21.20
+8.42(+65.88%)
Currency In USD
| Previous Close | 12.78 |
| Open | 21.12 |
| Day High | 21.23 |
| Day Low | 21.09 |
| 52-Week High | 21.23 |
| 52-Week Low | 5.64 |
| Volume | 78.36M |
| Average Volume | 2.74M |
| Market Cap | 2.19B |
| PE | -20.38 |
| EPS | -1.04 |
| Moving Average 50 Days | 10.83 |
| Moving Average 200 Days | 8.21 |
| Change | 8.42 |
If you invested $1000 in Day One Biopharmaceuticals, Inc. (DAWN) since IPO date, it would be worth $902.13 as of March 06, 2026 at a share price of $21.2. Whereas If you bought $1000 worth of Day One Biopharmaceuticals, Inc. (DAWN) shares 3 years ago, it would be worth $1,154.68 as of March 06, 2026 at a share price of $21.2.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio
GlobeNewswire Inc.
Yesterday at 1:30 PM GMT
Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs Transaction represents total equity value of approximately $2.5 billion SURESNE
Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance
GlobeNewswire Inc.
Feb 24, 2026 9:00 PM GMT
OJEMDA™ 2025 momentum reflected by Q4 and full year net product revenues of $52.8 million and $155.4 million, respectively 2026 U.S. net product revenue projected at $225 - $250 million Expanded pipeline with January 2026 acquisition of Mersana Ther
Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026
GlobeNewswire Inc.
Feb 10, 2026 1:30 PM GMT
BRISBANE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-